Syros Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
Syros Pharmaceuticals reported its third quarter 2024 financial results and provided an update on its ongoing clinical trial for tamibarotene.
OTC.Pink
Syros Pharmaceuticals' second quarter 2024 report details financial results, clinical trial progress, and strategic realignments.
OTC.Pink
Syros Pharmaceuticals reported a net loss of $3.7 million for the first quarter of 2024, alongside updates on their ongoing clinical trials for tamibarotene.